Deucravacitinib shows sustained efficacy and safety through 52 weeks in PsA

The phase 3 POETYK PsA-1 trial randomised 670 biologic-naive patients with active psoriatic arthritis to oral deucravacitinib 6 mg daily or placebo through week 16, with placebo patients switching to deucravacitinib thereafter. The trial reported significantly higher ACR20 response with deucravacitinib versus placebo at week 16 (54.2% vs 34.1%), with responses maintained or increased through week 52 and inhibition of structural damage observed at both timepoints; safety findings included low rates of serious adverse events and discontinuations, with no imbalances in cardiovascular events, malignancies, or opportunistic infections and no deaths reported.

Most relevant for: Biologic-naive patients with active psoriatic arthritis and elevated inflammatory markers with radiographic joint erosion.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.